Uridine triphosphate
Modify Date: 2025-08-23 19:33:17
Uridine triphosphate structure
|
Common Name | Uridine triphosphate | ||
|---|---|---|---|---|
| CAS Number | 63-39-8 | Molecular Weight | 484.14100 | |
| Density | 2.106 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C9H15N2O15P3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 113ºC | |
Use of Uridine triphosphateUridine triphosphate (UTP;Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that participates in glycogen metabolism and synthesis of RNA during transcription. |
| Name | utp |
|---|---|
| Synonym | More Synonyms |
| Description | Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that participates in glycogen metabolism and synthesis of RNA during transcription. |
|---|---|
| Related Catalog | |
| In Vitro | Uridine triphosphate treatment induces Schwannoma cell migration through activation of P2Y2 receptors and through the increase of extracellular matrix metalloproteinase-2 (MMP-2) activation and expression[1]. Uridine triphosphate-induced proliferation is mediated by protein kinase D, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, phosphatidylinositol 3-kinase (PI3K), Akt, and phospholipase D. Uridine triphosphate increases phosphorylation of Akt through protein kinase C, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, and PI3K[2]. |
| In Vivo | Uridine triphosphate reduces mitochondrial calcium levels following hypoxia. Early or late uridine triphosphate preconditioning is effective to reduce infarct size and superior myocardial function[3]. Uridine triphosphate treatment increases the number of monocytes and macrophages infiltrating the pouch and up-regulates the gene expression of IL-4 and IL-13 in the regional lymph nodes[4]. |
| Cell Assay | Pancreatic duct epithelial cells are treated with (0.1 μM-1 mM) uridine triphosphate. BrdU is added after different time points (12-24 hours). Proliferation is measured using the BrdU incorporation assay in triplicate[2]. |
| Animal Admin | Rats: Four main groups are tested: (1) sham without LAD ligation, (2) LAD ligation, (3) injected with UTP (0.44 µg/kg i.v.) 30 min before MI, (4) UTP injection (4.4 µg/kg i.v.) 24 h prior to MI. Several different concentrations of UTP are tested (0.044–44.4 µg/kg). Left ventricular systolic pressure (LVSP), end-diastolic pressure (LVEDP) and heart rates are monitored before, after UTP treatment and post MI[3]. |
| References |
| Density | 2.106 g/cm3 |
|---|---|
| Molecular Formula | C9H15N2O15P3 |
| Molecular Weight | 484.14100 |
| Flash Point | 113ºC |
| Exact Mass | 483.96900 |
| PSA | 293.80000 |
| InChIKey | PGAVKCOVUIYSFO-XVFCMESISA-N |
| SMILES | O=c1ccn(C2OC(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)C2O)c(=O)[nH]1 |
| Storage condition | −20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATAMUTATION DATA
|
| Precursor 9 | |
|---|---|
| DownStream 9 | |
CAS#:16628-81-2
CAS#:727398-81-4![1H-benzo[d][1,2,3]triazol-1-yl (((3aR,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxytetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl) (4-chlorobutyl)(methyl)phosphoramidate Structure](https://image.chemsrc.com/caspic/231/727399-01-1.png)
CAS#:727399-01-1
CAS#:58-97-9
CAS#:538-75-0
CAS#:362-43-6
CAS#:56-65-5
CAS#:58-96-8
CAS#:58-98-0
CAS#:1330004-15-3
CAS#:66-22-8
CAS#:302917-20-0
CAS#:22566-84-3
CAS#:13493-13-5
CAS#:65-47-4| uridine-triphosphate |
| Uteplex |
| [[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate |
| Uridine 5'-triphosphoric acid |
| uridine 5'-O-triphosphate |
| MFCD00274571 |
| 5'-UTP |
| uridine 5'-triphosphate |
| EINECS 243-347-5 |
| Uridine triphosphate |
| Uridine 5'-(tetrahydrogen triphosphate) |